Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Biosolution Co., Ltd. (086820:KRX), powered by AI.
Biosolution Co., Ltd. is currently trading at ₩6,970. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Biosolution Co., Ltd. on Alpha Lenz.
Biosolution Co., Ltd.'s P/E ratio is 661.0.
“Biosolution Co., Ltd. trades at a P/E of 661.0 (premium valuation) with modest ROE of 0.9%. 3Y revenue CAGR of 14.6% highlights clear growth momentum.”
Ask for details →Biosolution Co., Ltd. is a prominent player in the biotechnology sector, specializing in the development and commercialization of advanced bioengineering products and technologies. This company is primarily engaged in the creation of bio-based solutions for medical applications, including cell therapy and regenerative medicine, which are crucial for advancing modern healthcare treatments. Biosolution Co., Ltd. focuses on leveraging its expertise in stem cell research and technology to deliver innovative therapeutic products aimed at treating a variety of diseases and injuries. By emphasizing cutting-edge research and development, the company significantly contributes to enhancing treatment outcomes and expanding the potential of regenerative science. In the financial market, Biosolution Co., Ltd. plays a vital role as a technology-driven innovator within the healthcare industry, attracting attention for its potential to address unmet medical needs and for its contributions to scientific advancement. This underscores its significance in both healthcare and biotechnology sectors, where ongoing research can lead to breakthrough therapies and improved patient care.
“Biosolution Co., Ltd. trades at a P/E of 661.0 (premium valuation) with modest ROE of 0.9%. 3Y revenue CAGR of 14.6% highlights clear growth momentum.”
Ask for details →Biosolution Co., Ltd. (ticker: 086820) is a company listed on KRX in the Healthcare sector (Biotechnology). It has approximately 71 employees. Market cap is $180.7B.
The current price is ₩6,970 with a P/E ratio of 661x and P/B of 5.65x.
ROE is 0.86% and operating margin is -28.56%. Annual revenue is $15.2B.